Marketing Innovation: An Interview with Pavneet Gulati of Ceuticoz

An exclusive interview with Pavneet Gulati – Head of Marketing at Ceuticoz

In this insightful interview, Pavneet Gulati, Head of Marketing at Ceuticoz, shares her expertise on navigating the dynamic pharmaceutical landscape.

With a focus on innovative marketing strategies and customer engagement, she reveals how Ceuticoz is redefining its brand presence and connecting with healthcare professionals and consumers alike.

How has the medical aesthetics and cosmeceuticals industry evolved in recent years?

Pavneet Gulati: The medical aesthetics and cosmeceuticals industry has experienced significant transformation in recent years, driven by technological advancements, shifting consumer preferences, and scientific innovation.

Science-Backed Skincare is now the new standard. Consumers are no longer satisfied with just “natural” or “luxury” claims – they demand clinically proven, ingredient-focused, and dermatologist-recommended solutions.

Active ingredients such as retinoids, niacinamide, peptides, ceramides, and growth factors, all supported by data and research, have seen a rise in popularity. This has resulted in an increased trust in medical-grade and cosmeceutical brands that operate at the intersection of dermatology and skincare.

Medical aesthetics clinics are increasingly combining professional treatments (like lasers, microneedling, and chemical peels) with cosmeceutical support to enhance results. Many cosmeceutical brands are now developing post-procedure skincare lines aimed at healing, soothing, and maintaining clinical outcomes.

We are also witnessing the globalization of ingredient trends, with the rise of K-beauty, J-beauty, and Ayurvedic derivatives influencing global formulations. Indian-origin skincare brands, such as Ceuticoz, are emerging as globally competitive, offering science-driven products that deliver proven results and world-class quality.

The demand for personalized skincare is booming, fueled by AI skin analysis apps, tele-dermatology, and digital diagnostic tools. Consumers are now seeking custom routines tailored to their skin type, geography, lifestyle, and specific concerns, moving away from the one-size-fits-all approach.

Finally, social media has sparked the rise of a new generation of skintellectual consumers who actively research ingredients and demand transparency. Dermatologists and skincare professionals themselves have become influencers, building trust in science-led brands.

What are Ceuticoz’s expansion plans in India and international markets?

Pavneet Gulati: Ceuticoz is committed to strengthening its ethical market presence in India by becoming the preferred brand for clinical dermatology prescriptions.

We are enhancing medical engagement, expanding into Tier 2 and 3 cities, and launching education-driven initiatives to build trust. Following the success of our Ivorine Brightening Range, we are diversifying into post-procedure skincare solutions.

Internationally, Ceuticoz is present in 10+ countries, with a strong foothold in Canada and ongoing expansion in the Middle East and Southeast Asia. Our vision is to establish Ceuticoz as a leading global Indian cosmeceutical brand—trusted by dermatologists, loved by patients, and backed by science.

Which new markets or regions are you targeting in the coming year?

Pavneet Gulati: In the coming year, Ceuticoz is targeting the USA, UAE, and Saudi Arabia as key markets for expansion. These regions offer significant growth potential, with a rising demand for science-backed, dermatologist-recommended skincare products.

We are actively working on establishing strategic partnerships with local distributors, skincare clinics, and dermatologists to strengthen our presence and build trust within these markets.

Our goal is to position Ceuticoz as a leading choice in the global cosmeceutical space, offering high-quality, clinically proven skincare solutions to meet the diverse needs of consumers in these regions.

How is Ceuticoz differentiating itself from other cosmeceutical brands?

Ceuticoz is strategically differentiating itself from other cosmeceutical brands by combining clinical credibility, affordability, and Indian dermatological relevance—while gearing up for global competitiveness.

Every Ceuticoz product is clinically driven and dermatologically validated, designed to treat specific skin concerns like acne, pigmentation, sensitivity, and aging.

We use evidence-based actives like Tranexamic Acid, Niacinamide, Peptides, Retinoids, and patented ingredients with proven results.There is a major emphasis on derma-grade efficacy, not just cosmetic appeal, i.e. bridging the gap between pharmaceuticals and skincare.

Ceuticoz operates at the intersection of clinical dermatology and modern skincare, creating solutions that doctors trust and patients love. We boast of strong in-clinic presence and medical engagement with dermatologists across India.

Key Differentiator – Endorsed by dermatologists as both a treatment support and cosmetic enhancement, we offer medical-grade skincare at accessible prices, making science-backed skin health solutions available to a wider population.

This is highly relevant in India and other developing markets, where price often limits access to clinical-grade skincare.

Ceuticoz stands apart by offering dermatologist-backed, medical-grade skincare that is affordable, ethical, and globally relevant—while being deeply rooted in Indian dermatology and scientific integrity

What is Ceuticoz’s current total revenue, and what is the projected revenue for FY 2025-26?

Pavneet Gulati: Ceuticoz’s projected India revenue for FY 2025-26 is 50 Crores. This growth is driven by our efforts to expand our product portfolio, strengthen market presence, and enter new regions, both domestically and internationally.

Our focus on innovation, dermatologist collaborations, and community engagement will help achieve this target and ensure long-term growth.

How has the company performed in terms of year-on-year growth?

Pavneet Gulati: Last 3 year CAGR – 33%

What are the key financial highlights from the past year?

• Achieved highest-ever monthly sales in November and then in December in 2024 crossing 4 Cr
• Strong double-digit growth in revenue compared to the previous year
• Ceuticoz entered the Canadian market with 8+ SKUs, driving new international revenue streams.
• Operations started in Kenya and South Africa with more than 20 SKUs
• Strengthened ethical dermatology market presence in Odisha and Bengaluru, reinforcing a commitment to dermatological excellence.
• Launched 7 new skin brightening products under the sub-brand of IVORINE

Are there any plans for new product launches or R&D initiatives?

Pavneet Gulati: Yes, we are working to launch the pediatrics range with 7 products in September 2025. The formulation and packaging has been finalised for all the products and currently we have put them for clinical and consumer studies.

How does Ceuticoz plan to strengthen its global footprint?

Pavneet Gulati: By targeting regions with significant Indian and South Asian diaspora such as Canada (already launched), USA, UK, UAE and  Singapore.

These markets have a strong need for tailored skincare that addresses pigmentation, acne, sensitivity, and aging in melanin-rich skin—which Ceuticoz is uniquely positioned to serve.

One of the core areas of focus will be to build trust through medical endorsement, not just retail marketing. Partnering with international dermatologists and clinics to build credibility, Launching with a doctor-first model in key global cities, mirroring its Indian approach.

We will also be participating in international conferences and exhibitions (e.g., already showcased at the International Dermatological Conference, New Delhi and 5 international derma exhibitions in the last 2 years) to build authority and trust.

It is important to mention that we need to be globally compliant to unlock growth in regulated markets.We are already Investing in international regulatory approvals (like Health Canada, FDA-compliant labeling, EU guidelines) and Tailoring packaging and claims to local compliance and consumer preferences.

What are the company’s business targets for the next five years?

Pavneet Gulati: Ceuticoz’s India’s business targets for the next five years focus on achieving sustainable growth and expanding our global presence.

We aim for a CAGR of 30–35%, with a target revenue of ₹150–200 Cr by FY 2029-30, up from the current ₹25–30 Cr annual run rate. Our strategy will be driven by ethical markets, product diversification, and global expansion.

By FY 2030, we plan to derive 35–40% of our revenue from international markets, with a presence in more than 25 countries. Additionally, we aim to build a network of 30,000+ prescribing dermatologists and cosmetologists to strengthen our market position and ensure continued success.

Pavneet Gulati’s vision for Ceuticoz highlights the importance of creativity and adaptability in marketing.

By leveraging digital tools and storytelling, he is paving the way for impactful campaigns that resonate with audiences, ultimately enhancing the brand’s reputation and fostering trust in the pharmaceutical industry.

Explore Success story of Indian entrepreneurs & startups at SugerMint. Follow us on Twitter, Instagram, Facebook, LinkedIn